Detail Information of Xenobiotics
| General Information of Xenobiotics (ID: XEO00675) | ||||||
|---|---|---|---|---|---|---|
| Xenobiotics Name |
NVP-BKM120
|
|||||
| Xenobiotics Type |
Pharmaceutical Agent(s)
|
|||||
| Classification |
Drug in Phase 3 Clinical Trial
|
|||||
| Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=16654980"></iframe>
|
![]() |
||||
| 3D MOL | 2D MOL | |||||
| PubChem CID | ||||||
| DME(s) Modulated by This Xenobiotics | ||||||
| DME(s) Inhibited by This Xenobiotics | ||||||
| Aldo-keto reductase 1C3 (AKR1C3) | DME Info | Homo sapiens | [1] | |||
| References | ||||||
| 1 | Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.


